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ABSTRACT (IN MALAY LANGUAGE) 
Tujuan kajian ini adalah untuk menganalisa samada ujian-ujian rutin serologi dan 
hematoJogi makmal, boleh di gunak:an untuk pengesanan awal penyak:it hemolisis ABO 
bayi dan mendapatkan data-data untuk kajian epidemiologi berkenaan penyakit ini. 
Kajian ini adalah secara 'cross-sectional' perbandingan ke atas bayi-bayi yang di 
lahirkan oleh ibu-ibu yang mempunyai kumpulan darah 0 resus positif di Bilik Bersalin, 
HUSM dari Oktober, 2000 hingga Jun, 2001. Spesimen darah dari talipusat bayi-bayi 
yang memenuhi kriteria diambil dan di uji untuk hemoglobin, bilirubin, pengiraan 
reticuJosit, DAT, pengiraan sperosit dan pengiraan NRBC per 100 WC. Kemudian 
keputusan ujian-ujian tersebut dianaJisa secara statistik. Data-data gambaran klinikal dan 
pengurusan rawatan bayi-bayi di ambil dari buku rawatan pesakit dan hubung-kaitnya 
dengan keputusan ujian darah dari tali-pusat bayi dikaji. Anggaran insiden dan keterukan 
penyakit hemolisis ABO bayi di buat dengan data-data yang di perolehi. 
Keseluruhannya, 85 bayi iaitu 34 dengan ketidak-serasian ABO dan 51 dengan 
keserasian ABO memenuhi kriteria untuk kajian ini. Hemoglobin, pengiraan sperosit dan 
DA T di dapati mempunyai perbezaan yang sah secara statistik di antara kumpulan yang 
mempunyai ketidak-serasian ABO dan yang mempunyai keserasian ABO. Secara 
klinikal, lima bayi yang mempunyai ketidak-serasian ABO di dapati jandis dengan dua 
IX 
daripada mereka telah menerima rawatan terapifoto dan tiada 'exchange transfusion' di 
perlukan. Insiden ketidak-serasian ABO di kalangan bayi-bayi di HUSM ialah 15.6%. 
Insiden penyakit hemolisis ABO bayi ialah 2.3%. Insiden bagi bayi yang mempunyai 
ketidak:-serasian ABO memerlukan terapifoto di sebabkan penyakit hemolisis ABO bayi 
ialah 6.7% dan insiden untuk semua bayi memerlukan terapifoto di sebabkan penyakit ini 
pula ialah 0. 92%. 
Tiada hubung-kait yang jelas di antara gambaran klinikal dan keputusan ujian 
makmal. Ujian darah menerusi talipusat bayi, tidak boleh di cadangkan sebagai cara 
untuk ujian pengesanan awal untuk penyakit hemolisis ABO bayi. Ujian darah talipusat 
bayi adalah tidak sensitif dan spesifik berkemungkinan kerana keadaan penyakit tersebut 
yang tidak: seri us di HUSM Insiden dan keterukan penyakit hemolisis ABO bayi di sini 
adalah hampir menyamai peratusannya di Amerika Utara dan Eropah. 
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ABSTRACT (IN ENGLISH) 
The study was to evaluate whether the routine serological and haematological laboratory 
tests could be used for an early diagnosis of ABO HDN and to obtain epidermiological 
data. 
This is a comparative cross-sectional study of newborn babies born to blood 
group 0 rhesus positive mothers in labour room of HUSM from October, 2000 to June, 
2001. Specimens from cord blood of suitable babies were collected and investigated for 
haemoglobin, bilirubin, reticulocytes count, DAT, spherocytes count and NRBC per 100 
WC. The results were analysed statistically. The clinical features and management data of 
ABO incompatible babies were taken from management file and correlation made with 
the cord's blood findings. The incidence and severity of ABO HDN were also estimated 
from the data. 
Altogether 85 babies ie 34 ABO incompatible and 51 ABO compatible. The 
haemoglobin, spherocytes count and DA T showed a statistically significant difference 
between ABO incompatible and ABO compatible babies. Clinically five babies of ABO 
incompatible noted to be jaundice with two of them received phototherapy but exchange 
transfusion was not needed in any of them. The incidence of ABO incompatible infants in 
HUSM is 15.6%. The incidence of ABO HDN is 2.3%. The incidence of ABO 
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incompatible infants requiring phototherapy due to ABO HDN is 6. 7% and the incidence 
of all infants requiring phototherapy due to ABO HDN is 0. 92%. 
There is poor correlation between the clinical features and laboratory findings. 
The cord blood tests therefore can not be recommended as method of early diagnosis of 
ABO HDN. The cord blood tests were not sensitive and specific probably due to 
mildness of ABO HDN in HUSM. The incidence and severity of ABO HDN here are 
almost comparable to the figures of North America and Europe. 
xn 
Chapter 1 
INTRODUCTION 
1 
1.0 INTRODUCTION 
1.1 DEFINITION 
Haemolytic disease of the newborn (HDN) is a condition in which the life 
span of the infant's red cells is shortened by the action of specific antibodies 
derived from the mother by placental transfer. The disease begins in intra-uterine 
life and is therefore correctly described as haemolytic disease of the fetus and 
newborn but the simple term haemolytic disease of the newborn has been used for 
a long time and can be taken to include haemolytic disease of the fetus (Mollison 
et al.l997). 
HDN is also defined as a disease characterised by the destruction of fetal I 
newborn red cells resulting from the placental transfer of maternal alloantibody 
(Strohm 1995). 
The placental transfer of maternal alloantibody is only of IgG class. 
The commonest IgG red cell antibodies in human serum are anti-A and anti-B and 
relatively high concentrations are found only in group 0 subjects (Mollison et al. 
1997). This is because the group 0 individuals are "naturally" pre-sensitised to A 
and B antigens by exposure to ABO-I ike substances found in food or other 
exogenous sources (Foerster 1992). The anti-A and anti-B occurring in group B 
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and A subjects respectively, are almost of IgM variety that cannot cross the 
placental barrier. 
The disease cause by these anti-A and anti-B are usually termed as ABO 
HDN and for practical purposes, it is restricted to A orB individuals with mothers 
of 0 (Mollison et al.1997). However, group B infants of group A (particularly A2) 
mothers occasionally are affected (Strohm 1995). 
There are many other antibodies that can cause HDN. The list of antibodies 
in table 1.1 below, includes most but not all of those which can occur as IgG and 
known to have caused HDN. 
Table 1.1: Alloantibodies reported to cause HDN (Adapted from Mollison et al. 
1997). 
Within the Rh system Anti-D -c -C -Cw -Cx -e -E -Ew -ce -
'', '''' '' Ces -Rh32 -Goa -Bea -Evans -L W 
' ' ' ' ' 
Outside the Rh system Anti-K -k, -Ku -Kp8 -Kpb -Js8 -Jsb -Fy8 
, ' ' ' '' ' 
-Fy3 -Jk8 -Jkb -M -N -S -s -U -Vw -Far 
' ' ' ' '''' ' ' 
-Mv -Mit, -Mta -Mur -Hil - Hut -En8 -PP 
' ' , ' , , , 
pk L 8 L b L 9 D ·8 D ·b 8 b 
- - u - u - u - 1 1 -Yt -Yt -
' , ' ' ' ' , ' Do a -Co a - Wra , , 
Antibodies to high- Anti -At8 -J ra - Lan -Ge ' , , 
incidence antigens 
Antibodies to low- Anti-Bi, -By, -Fr8 , -Good, -Rd, -Re8 , -Zd 
incidence antigens 
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1.2 HISTORICAL ASPECTS 
In 1609, a French midwife, Louyse Bourgeois, writing in the popular Paris 
press, was the first to describe haemolytic disease of the newborn. She reported 
the birth of twins: the first twin was bloated with fluid (hydropic) and died shortly 
after birth; the second appeared weii but rapidly became jaundiced (icterus 
gravis), lay in a position of opisthotonos and died (kernicterus). These two 
conditions ie hydrops fetalis and kernicterus (yellow staining of the brain) were 
described in detail by pathologists at the turn of the century but were not thought 
to be the same entity until 1932 (Bowman 1998). 
In 1932, Diamond and co-workers showed that hydrops fetalis, icterus 
gravis, and kernicterus were simply different spectra of the same disease 
characterised by hemolytic anaemia, extramedullary erythropoiesis, 
hepatosplenomegaly and the out-pouring of immature nucleated red blood cells 
(Naiman 2001). The ABO HDN was however, first described in 1944 by 
Halbrecht (Brouwers et al. 1988a ). 
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1.3 PATHOPHYSIOLOGY 
In humans, the transfer of antibodies from mother to fetus takes place o!"'Jy 
via the placenta. The onJy immunoglobulin transferred is IgG, which is bound by 
an Fe receptor on the plasma membrane of the placenta. The transfer ofigG is an 
active process a.11d takes place opJy from mother to fett!S and not in the reverse 
direction. 
~tm1re J ~· nt~Hl"1"~ffi 11hnunno- thP fPtn c tT\ reJ~tlon tn nbcPnta ~nfi lltPTtnP Ul~l! 
_._.._b-... ,a,..,;,_,__ ... _bl \.4...l .au• • '-'""" .. b"-.._._ ..._ _ .... .,.._..., ........... a'-+~~.J ••"-vy•---'" ~ ....... - .._ .. ._. ..__,."""". 
I Arnniotic fluid 
{ A rbntPri !f~ Q TT\ n rth' 0 iJ~ iannndll" <1 i G{l)( \ , .. .. --_t-~"--- .£ ....... .......... ..... & .. 5l.i...._,~ ... ...... ..... , • 7 .... -; . 
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Umbilical 
cord 
Placenta 
Fetus 
The sensitisation of mother's immune system or alloimmunisation 
increase \vith each incompatible pregnancy. The primary stimulus for 
i11'.n1unisation, in addition to exposure to ABO-like substances such as found in 
food, can also be a previous blood transfusion or abortion. Formation ofRh 
a.11tibodies is the most common form of alloimmunisation to give rise to clinically 
import..ant disease. Hovvever during pregnancy, ABO immunisation occurs more 
often t.~Jan Rh immunisation (Wells and Isbister, 1997). 
ABO HDN is quite different from HDN due either to anti-D or other blood 
group antibodies. ft.Jlti-A and anti-B, \vhich bind complement in adults, cause 
violent, life-threathening intravascular hemolysis after transfusion of ABO-
incompatible blood Ho\vever fetal ABO HDN is usually much milder than D, c 
and K forms ofHDN. 
Several reasons can be listed for the paradoxical mildness of PJ30 HD~J. 
First, there are fe\ver A and B antigeP..ic sites on the fetal RBC membrane ... AJso, 
anti-A and anti-B (with very rare exception; Pujol et al. 1991) do not activate 
complement on the fetal RBC membrane (Wang and Des forges, 1971; Brou'Ners 
et al. 1988b ). Second, anti-A and anti-B are mostly IgM, \vhich does not cross the 
placenta (Ramasethu and Luban, 2001 ). Third, the small amounts oflgG anti-A 
and anti-B that do traverse the placenta have myriad antigenic sites other than 
those on P-.BCs, other tissues, and secretions to \vhich they may bind. Only a very 
sma11 proportion of the minor amount of anti-A or anti-B that crosses the placenta 
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adheres to antigen on the fetal RBC membrane (Bo\\l111an 1998). Fourth, the 
severity may be related to IgG subclass. IgG2 constitutes a significant component 
of anti-A and anti-B antibody; this subclass oflgG is transported less readily 
across the placenta than are IgGl or IgG3 and is a less efficient mediator of 
macrophage-induced red cell clearance (Ramasethu and Luban, 2001 ). 
Table 1.3: Properties of human IgG subclasses (Parslo\v 1997). 
I igGl I lgG2 IgG3 IgG4 
_i 
Abundance(% oftotai IgG) 70 I 20 6 4 I 
1 Half-life in semm (days) 23 I 23 7 23 I I 
Placental passage -1 I I I I -1 I I I I I I I I I 
' 
i 
1 Complement fixation + I + I 
+++ 
-
I I I 
( Binding to Fe receptors +++ + I +++ -
The relative concentrations of the four subclasses vary some\vhat among 
individuals. It appears that the propensity to produce IgG antibodies of one 
subclass or another is at least partly an inherited trait (Parslo\v 1997). The 
antibodies with the subclass with the highest titre, strongly influence the result of 
the DAT, and in many cases of ABO incompatibilities these are IgG2 antibodies. 
Ho\vever, it has been reported that in infants \vith severe ABO HDN, the IgG 
subclasses bound to cord red cells are IgG 1 and I or IgG3 in addition to IgG2 
(Ukita eta!. 1989). 
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1.4 INCIDENCE 
Incidence of ABO HDN depends on incidence of ABO incompatibility. It 
should be noted however that ABO incompatibility is not synonymous with ABO 
HDN. In other words, ABO HDN is the extreme end of the spectrum of ABO 
incompatibility. 
ABO hemolytic disease must be defined before its incidence can be 
estimated. For example, taking the criterion of the development of jaundice within 
24 hours ofbirth, the incidence was estimated by Halbrecht (1951) to be one in 
180; taking the faintest trace of jaundice in the first 24 hours as the criterion the 
incidence was found by Valentine (1958) to be as high as one in 70. In a study by 
Meberg and Johansen (1998), the ABO incompatible babies that required 
phototherapy were one in 106 or 0. 94% of all term infants. 
Cases ofHDN due to anti-A or anti-B which are severe enough to need 
exchange transfusion are relatively rare for examples three of 8000 births (Ames 
and Lloyd 1964 ); six of 5704 newborn infants (Voak and Bowley 1969); none 
amongst 534 infants born to group 0 mothers (Meberg and Johansen 1998). 
A higher incidence has been found in some other populations. The 
incidence of ABO HDN was found to be substantially higher in Venezuela, in 
which about 30% of ABO incompatible infants have signs of haemolytic disease 
8 
compared with 20% or less in European and North American populations (Cariani 
et al. 1995). The disease was found to be commoner in Blacks by Kirkman 
( 1977). Peevy and Wiseman ( 1978) also support the evidence concerning racial 
differences but not in the severity of ABO HDN between black and white infants. 
In a survey in Nigeria, the frequency of ABO HDN is about 5% of births 
(Worlledge et al. 1974). 
Al-Jawad et al. (1985) in their study concluded that ABO HDN was about 
as common in Arabs as in Blacks and that the disease tended to be more severe in 
Arab than in Europeans; exchange transfusion for ABO HDN was carried out on 
one in every 500 newborn Arab infants. Romano et al. (1994) in their study noted 
about one in 300 of all newborn infants in Venezuela need exchange transfusion. 
However, a study in multi-ethnic hospital in USA concluded that there 
was no significant difference in prevalance of clinical disease, which requires 
exchange transfusion among Asian, Black, Hispanic and Caucasian infants (Toy 
et al. 1988). Their study shows that in a sample of over 10,000 infants, ethnic 
differences were detectable in the laboratory but not in clinical disease. 
Locally, in HUSM, a study by Siti Aesah (1995), from the period of 
October, 1994- January, 1995, found that, out of total of 58 babies with neonatal 
jaundice (NNJ) who were admitted to Neonatal Intensive Care Unit (NICU), only 
9 
two need exchange transfusion and there were due to ABO HDN. The study also 
concluded that 12.1% of the NNJ babies were ABO HDN. 
Ho (1992) has review many studies on incidence of ABO incompatibility 
among jaundice baby. The review is summarised in table 1.4. 
Table 1.4: The incidence of ABO maternal- infant incompatibility among 
jaundice baby. 
Country Year % among cases of jaundice 
Australia 1983 7.1 
China, Beijing 1989 20 
Hong Kong 1970 15.6 
Hong Kong 1986 12.5 
Singapore 1988 16.6 
Singapore 1991 15.9 
India, New Delhi 1987 12.2 
India, Madras 1987 38.2 
In relation to DA T positive, the incidence in the cord blood of ABO 
incompatible babies are about 25% -30% (Bowman 1989). Toy et al. (1988) have 
done a prevalence study of ABO maternal-infant incompatibility in Asians, 
Blacks, Hispanics and Caucasians from 10 611 consecutive infants born over a six 
10 
years period. They have found that the prevalence of a positive DAT among 
group A infants born to 0 mothers was different among the four groups and 
highest in Asians (50%), follo\ved by Hispanics (42%), Blacks (40%) and 
Caucasians (31% ). The positive DAT rates were not different among the four 
groups of B infants born to 0 mothers with Asians showing positivity of 39%. 
The prevalence of positive DATs in all births was 6, 5, 5 and 4% respectively in 
the four groups. 
Another study in Bangkok, Thailand ( Chuansumritet al. 1997) found that 
the positive rate ofDAT in the ABO incompatible group were 54.5% by a 
conventional spin-tube technique and 50% by a gel technique. In the ABO 
compatible the positive rate of the DAT were 2.6% by the conventional and 
10.5% by the gel technique. 
I 1 
1.5 CLINICAL FEATURES 
1.5.1 SPECTRUM OF HDN 
HDN irrespective of whether it cause by ABO, Rhesus or other alloantibodies can 
occur in various forms. 
In its least severe form, HDN manifests itself as a mild haemolytic 
anaemia. The infant's red cells, coated with maternal lgG antibodies, are removed 
prematurely from the circulation, causing slight jaundice (maximum on the 
second to third days of life) and mild anaemia during the second week of life. 
More severely affected infants show severe hyperbilirubinaemia in the neonatal 
period, a condition which was called icterus gravis neonatorum. Prompt treatment 
with exchange transfusion is necessary to prevent bilirubin impregnation of the 
basal ganglia and neurological damage, a condition known as kernicterus. This 
condition may be fatal, or lead to serious neurological deficit, with deafness, 
mental retardation, choreo-athetosis and spasticity. 
In the most severely affected cases, profound anaemia develops in utero, 
and intrauterine death may occur at any time from the eighteenth week of 
gestation. Affected fetuses are pale and oedematous, with marked ascites. The 
placenta is bulky, swollen and friable. This condition is known as hydrops fetalis, 
and had a high mortality rate until ultrasound-guided intravascular transfusions 
12 
and improved intensive care facilities for very premature babies were introduced. 
The pathophysiology of hydrops is not fully understood, but extravascular 
haemolysis with fetal anaemia seems to play a major role by stimulating 
extramedullary erythropoiesis in the liver, with distortion of the hepatic 
circulation, leading to portal hypertension and impaired albumin production. 
Hypoalbuminaemia leads to ascites, oedema and pleural I pericardia! effusions. In 
addition, the severe anaemia leads to cardiac failure and tissue hypoxia, which 
damages the endothelium, leading to fluid extravasation into extravascular space. 
13 
1.5.2 COMMON MANIFESTATION 
ABO HDN is far more comman than Rh HDN but clinical presentation is usually 
mild and rarely responsible for fetal deaths (Ramasethu and Luban, 2001 ). The 
most common manifestation is jaundice which appear during first 24 hours of life, 
but it is not as pronounced and rarely is sufficiently severe to cause complications 
such as kernicterus. The anaemia is correspondingly mild, pallor is uncommon 
and hydrops fetalis is exceedingly rare. Mild degrees of hepatosplenomegaly may 
be observed (Foerster 1992). 
First-born infants are affected as frequently as those born subsequently in 
which they are 40% - 50% of all HDN (Ramasethu and Luban, 2001 ). In families 
in which ABO HDN is mild, an affected infant may be followed by a clinically 
unaffected infant. On the other hand, when severe disease occurs it is likely to be 
followed by similarly severe disease in subsequent infants of the same blood 
group (Moiiison et al. 1997). 
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1.6 LADORA TORY FINDINGS 
1.6.1 SEROLOGY 
ABO GROUP: Mothers of infants with ABO HDN almost invariably 
belong to group 0. However, in one series of 45 cases, reported by Munk-
Andersen (1958), the mother was group 0 in 43 instances and subgroup 
A2 in the remaining two; A2 mothers produced much stronger 
'incomplete' anti-B than AI mothers. The affected infants are either 
belong to group A or B. 
THE DIRECT ANTIGLOBULIN TEST (DAT): The infant's red cells 
often give a negative or only weakly positive reaction to the DAT (Ukita 
et al. 1989). This failure of antibody-sensitised fetal cells to agglutinate 
with antiglobulin sera may be a function of the smaller number of 
antibody molecules sensitising these fetal cells (Ramono et al. 1973), 
which in turn may, at least in part, reflect the greater distance between 
sites in fetal cells as compared to the distance in adult cells (Voak and 
Williams, 1971 ). 
Merry et al. ( 1984) has found correlation between agglutination 
strength and the number of lgG molecules bound per cell in the DAT. In 
normal subjects with a negative DA T the number of IgG molecules per red 
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cell was found to be in the range 5-90. The findings of Jeje et al. (1984) 
were almost identical to this. Some studies has found that when the spin-
tube antiglobulin test is used, the minimum number of antibody molecules 
which can be detected is about 100- 150 (Romano et al. 1973; Burkart et 
al. 1974; Stratton et al. 1983). 
In a study by Chuansumrit et al. ( 1997) which compared DAT 
using gel technique and the conventional spin-tube technique, found that 
the positive rate in the ABO incompatible group was similar by both 
techniques. However the scores by the gel technique were higher than 
those of the conventional technique. 
IgG ANTI-A AND ANTI-B OF MOTHERS: The test can be done by 
treating the mother's serum with a reducing agent to inactivate IgM 
antibodies and then determine the anti-A or anti-B titre by lA T using an 
anti-IgG serum (American Association of Blood Banks, 1996). Using this 
method a titre of 512 or more was found to be very suggestive of 
haemolytic disease (Mollison et al.1997). 
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1.6.2 HAEMATOLOGICAL 
HAEMOGLOBIN CONCENTRATION: Normal cord blood value is 
15.3±1.3 g/dl (Diagne et al.1995). Anaemia is taken as Hb concentration< 
14.0 g/dl. In moderately severe ABO HDN the Hb concentration of cord 
blood may be below normal limit. ABO HDN is a shot-lived affair and it 
is unusual for anaemia to be found after the first 2 weeks or so of life. 
RETICULOCYTOSIS: A slight increase in reticulocytes is common 
feature in HDN due to ABO incompatibility (Rosenfield 1955). In the 
series of fairly severe cases collected by Crawford et al. (1953), the 
reticulocytes count exceeded 15% in six of 11 cases. 
ERYTROBLASTAEMIA: The same study by Crawford et al (1953) also 
noted 5 of the 11 cases were having 30 or more nucleated red cells per 100 
leukocytes. Latest study by Hanlon-Lundberg and Kirby (2000) found an 
association between ABO incompatibility and elevation in NRBC even 
with mild clinical courses. 
SPHEROCYTOSIS: Spherocytes are cells which are more spheroidal (less 
disc-like) than normal red cells. Their diameter is less and their thickness 
greater than nonnal. Only in extreme instances are they almost spherical in 
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shape. Spherocytes has been described as a feature of ABO HDN but not 
seen in Rh HDN (Oski and Naiman, 1982). 
SERUM BILIRUBIN: Fetal serum bilirubin is maintained at a low level 
(<2.0 mg/dl) exclusively by placental clearance. Even in situations of 
markedly increased fetal bilirubin production fetal serum bilirubin 
concentration rarely exceed 5 to 7 mg/dl (Whitington and Alonso, 1998). 
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1.6.3 SPECIAL TESTS 
IgG SUBCLASSES OF ANTI-A AND ANTI-B: Anti-A and anti-B from 
pregnant women are at least partly IgG2. Macrophages carrying the high-
affinity Fclla receptor mediate lysis of red cells sensitised with IgG2 anti-
A, although not that of cells sensitised with IgG2 anti-Rh D (Kumpel et al. 
1996). Presumably, therefore, IgG2 anti-A and anti-B play a part in red 
cell destruction in those infants with ABO HDN whose macrophages carry 
the high-affinity Fclla receptor. 
ANTIBODY -DEPENDENT CELL-MEDIA TED CYTOTOXICITY 
ASSAYS (ADCC) AND ANTIGEN DENSITY OF A AND B: Brouwers 
et al ( 1988a) in a study of ABO HDN has measured the lytic effect of lgG 
anti-A or anti-B from maternal blood samples by ADCC with monocytes 
as effector cells. The antibodies were considered to induce lysis when 
more than 10% of the target cells were lysed. In the cord blood samples 
they have also measure the relative antigen density of the A or B antigen 
by ELISA technique. The relative antigen density was expressed as the 
percentage of the reaction with the most strongly reacting cord-blood red 
cells and was considered to be high when the antigen density was more 
than 65%. They have found that the degree of lysis was strongly affected 
by the number of A or B sites on the red cel1s. 
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DIRECT ENZYME-LINKED ANTIGLOBULIN TESTS (ELAT): Kiruba 
et ai (1988) has studied usefulness ofELAT in detecting sensitised cells in 
haemolysis of the newborn due to ABO incompatibility. The technique 
which used an ELISA reader to measure absorbance of the sample was 
found to be more sensitive than the DAT. 
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1.7 MANAGEMENT 
1.7.1 ANTENATAL SCREENING 
Many workers have tried to use immunoglobulin class and titer of 
maternal ABO antibodies to predict ABO HDN. These tests are laborious 
and at best demonstrate the presence of IgG maternal antibody but do not 
correlate well with the degree of fetal RBC destruction (Kennedy and 
Abdul Wahee<L 1999). Consequently, detection of ABO HDN is best done 
after birth. 
1.7.2 EXCHANGE TRANSFUSION 
The key to the management of HDN is exchange transfusion, which was 
introduced by Wallerstein in 1945 (Bowman, 1998). Since severe anaemia 
is very uncomman, the main indication for exchange transfusion is the 
threat of serious hyperbilirubinaemia, leading to kernicterus. When 
exchange transfusion is judged to be necessary, group 0 blood should be 
used. Provided that the donor's plasma has been screened so as to exclude 
donors with potent anti-A or anti-B, the antibodies in the transfused 
plasma are unlikely to exacerbate the haemolytic process. 
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1. 7.3 PHOTOTHERAPY 
The mode of action of phototherapy in lowering serum bilirubin 
concentration is that, on exposure to light, particularly in the region of 4 20 
- 480 run, bilirubin is converted to the non-toxic pigment, biliverdin. In 
those full-term infants with ABO HDN whose serum bilirubin 
concentrations threaten to rise to dangerous levels, photothempy is often 
sufficient to control situation. 
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1.8 RATIONALE OF THE STUDY 
Since 1944 when the ABO HDN was first described by Halbrecht, many 
investigators have tried to find a simple test to predict whether the baby will be 
affected. 
Toy et al. (1988) considered DATto be the best laboratory predictor of 
severity of ABO HDN. Menon and Mohapatra (1987) found the quantitative 
estimate of spherocytes a good predictor of ABO incompatibility, whereas the 
DATwas a better predictor of severe haemolytic disease. However, Quinn et al 
(1988) mentioned that, in the individual case, Coombs' positivity and I or a strong 
positive elution test may be a helpful predictor of jaundice, but not of its severity. 
Kiruba et al (1988) introduced ELAT as more sensitive test than DAT. 
However, ELAT may be good for epidemiology study but not good enough for 
routine use since it specificity still low. Later Chuansumrit et al ( 1997) have 
compared the DAT done using the conventional spin-tube technique with a simple 
and technically less demanding gel technique. They found that although the 
positive rate ofDAT in the ABO incompatible group was similar, the scores by 
the gel technique were higher than those of the conventional technique. 
Brouwers et al (1988a) suggested that the combination of the antibody-
dependent cell-mediated cytotoxicity (ADCC) assay with the density of A or B 
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antigens on cells provides a good screening test for ABO incompatibility. The 
drawback of the tests was that it not widely available and expensive for routine 
use. Further more in the West, some clinicians (e.g. Quinn et al1988) were 
doubted whether ABO incompatibility matters. A population based study of 2463 
infants with 554 ABO incompatibility by Meberg and Johansen ( 1998) has found 
that no exchange transfusion required in any of the infants. In fact, no kernicterus 
has occurred in their population since 1970. 
There were however significant different of behaviour of ABO maternal-
infant incompatibility among races. The study in the multiethnic hospital in USA 
by Toy et al (1988) found that the prevalence of positive DAT results were 
highest in Asian followed by Black, Hispanic and Caucasian. There were also 
different in incidence and severity among Nigerian's Black and Arab. The Arab 
for example was reported to required exchange transfusion for ABO HDN in one 
out of 500 newborn infants. 
There were not many studies in Malaysia in the subject of ABO HDN per 
se. Many studies were on neonatal hyperbilirubinaemia or jaundice. The local 
HUSM study, on neonatal indirect hyperbilirubinaemia by Siti Aesah (1995) in 
Neonatal Intensive Care Unit (NICU) from period of October, 1994- January, 
1995 has studied total of 58 babies. 
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